{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-22T14%3A10%3A53.393Z®isteredInterest=false&max-date=2019-05-16&max-questionFirstAnswered.=2019-05-22T14%3A50%3A46.107Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-22T14%3A10%3A53.393Z®isteredInterest=false&max-date=2019-05-16&max-questionFirstAnswered.=2019-05-22T14%3A50%3A46.107Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-22T14%3A10%3A53.393Z®isteredInterest=false&max-date=2019-05-16&_metadata=all&max-questionFirstAnswered.=2019-05-22T14%3A50%3A46.107Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&_page=0&min-answer.questionFirstAnswered.=2019-05-22T14%3A10%3A53.393Z®isteredInterest=false&max-date=2019-05-16&max-questionFirstAnswered.=2019-05-22T14%3A50%3A46.107Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-22T14%3A10%3A53.393Z®isteredInterest=false&max-date=2019-05-16&max-questionFirstAnswered.=2019-05-22T14%3A50%3A46.107Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-22T14%3A10%3A53.393Z®isteredInterest=false&max-date=2019-05-16&max-questionFirstAnswered.=2019-05-22T14%3A50%3A46.107Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1127168", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127168/answer", "answerText" : {"_value" : "

In England, it is the responsibility of National Health Service commissioners to make decisions on individual treatments for urinary tract infections on the basis of the available evidence, taking into account guidance from the National Institute for Health and Care Excellence (NICE) where available. NICE guidance is always evidence based, adhering to the latest clinical thinking and research to determine the best treatment for patients.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-22T14:26:35.707Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Urinary Tract Infections"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce unplanned hospital admissions resulting from urinary tract infections.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4523", "label" : {"_value" : "Biography information for Catherine West"} } , "tablingMemberConstituency" : {"_value" : "Hornsey and Wood Green"} , "tablingMemberPrinted" : [{"_value" : "Catherine West"} ], "uin" : "255355"} , {"_about" : "http://data.parliament.uk/resources/1127170", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127170/answer", "answerText" : {"_value" : "

NHS Digital\u2019s Hospital Episodes Statistics publishes data on finished consultant episodes with a primary or secondary diagnosis of urinary tract infection broken down by financial year, rather than by calendar year.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-22T14:28:15.513Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Urinary Tract Infections"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans his Department has to improve the (a) reporting and (b) tracking of urinary tract infections in the NHS; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4523", "label" : {"_value" : "Biography information for Catherine West"} } , "tablingMemberConstituency" : {"_value" : "Hornsey and Wood Green"} , "tablingMemberPrinted" : [{"_value" : "Catherine West"} ], "uin" : "255357"} , {"_about" : "http://data.parliament.uk/resources/1127289", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127289/answer", "answerText" : {"_value" : "

The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.<\/p>

The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-22T14:32:11.803Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : " Drugs: Prices"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the affordability of medicines as a result of the redrafted WHO resolution entitled, Improving the transparency of markets for medicines, vaccines and other health-related technologies proposed by Italy on 29 April 2019.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4651", "label" : {"_value" : "Biography information for Dan Carden"} } , "tablingMemberConstituency" : {"_value" : "Liverpool, Walton"} , "tablingMemberPrinted" : [{"_value" : "Dan Carden"} ], "uin" : "255695"} , {"_about" : "http://data.parliament.uk/resources/1125504", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1125504/answer", "answerText" : {"_value" : "

The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom\u2019s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.<\/p>

The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.<\/p>

The JCVI\u2019s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.<\/p>

The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI\u2019s minutes which are attached.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "attachment" : {"_about" : "http://data.parliament.uk/resources/1125504/answer/attachment/1", "fileName" : {"_value" : "JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf"} , "title" : "JCVI Minute 2015"} , "dateOfAnswer" : {"_value" : "2019-05-22", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL15600"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-22T14:50:14.54Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-08", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pneumococcal Diseases: Vaccination"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what assessment they have made of the recommendations by the Joint Committee on Vaccination and Immunisation to reduce the infant pneumococcal vaccination schedule from three doses to two.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1850", "label" : {"_value" : "Biography information for Baroness Masham of Ilton"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Masham of Ilton"} ], "uin" : "HL15599"} , {"_about" : "http://data.parliament.uk/resources/1125505", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1125505/answer", "answerText" : {"_value" : "

The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom\u2019s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.<\/p>

The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.<\/p>

The JCVI\u2019s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.<\/p>

The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI\u2019s minutes which are attached.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "attachment" : {"_about" : "http://data.parliament.uk/resources/1125505/answer/attachment/1", "fileName" : {"_value" : "JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf"} , "title" : "JCVI Minute 2015"} , "dateOfAnswer" : {"_value" : "2019-05-22", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL15599"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-22T14:50:14.483Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-08", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pneumococcal Diseases: Vaccination"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what analyses they have conducted of the risks and benefits of reducing the infant pneumococcal vaccination schedule from 2+1 to 1+1; and whether they will publish the results any such analyses.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1850", "label" : {"_value" : "Biography information for Baroness Masham of Ilton"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Masham of Ilton"} ], "uin" : "HL15600"} , {"_about" : "http://data.parliament.uk/resources/1125506", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1125506/answer", "answerText" : {"_value" : "

Public Health England, in partnership with NHS England and the Department, is taking steps to improve vaccination coverage in England, including for people living with HIV.<\/p>

These steps include initiatives to improve access to the immunisation programme; communication with the public; data to identify underserved individuals and populations; and training for healthcare professionals, changes to vaccination eligibility criteria; launching disease elimination strategies; running targeted social media campaigns; providing information leaflets in multiple languages and running e-learning programme for healthcare practitioners.<\/p>

Certain vaccines are delivered through sexual health services that particularly benefit people living with HIV. This includes vaccines for hepatitis A, hepatitis B and human papillomavirus. People living with HIV are in the influenza risk groups and are invited for the flu vaccine on an annual basis.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-05-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-22T14:50:46.107Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-08", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "HIV Infection: Vaccination"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what steps they are taking to improve vaccination coverage for people living with HIV.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1850", "label" : {"_value" : "Biography information for Baroness Masham of Ilton"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Masham of Ilton"} ], "uin" : "HL15601"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 6, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }